| 替吉奥治疗晚期乳腺癌的研究进展 |
| 投稿时间：2015-02-09 修订日期：2015-06-04 点此下载全文 |
| 引用本文：郑婷,钱其军.替吉奥治疗晚期乳腺癌的研究进展[J].药学实践杂志,2015,33(6):557~560 |
| 摘要点击次数: 1426 |
| 全文下载次数: 178 |
|
| 基金项目:国家科技重大专项(No.2013ZX10002-010-007) |
|
| 中文摘要:替吉奥(S-1)是第三代氟尿嘧啶衍生物的口服抗癌剂,毒副作用小、疗效确切、给药方便。在大量的临床试验及不断的临床应用中,其展示出对晚期乳腺癌(advanced breast cancer,ABC)治疗的良好效果,将来有望成为乳腺癌治疗的一线化疗药物。 |
| 中文关键词:替吉奥(S-1) 晚期乳腺癌 化疗药物 |
| |
| Progress on S-1 in the treatment of advanced breast cancer |
|
|
| Abstract:S-1 is the third generation of fluorouracil derivative anti-cancer agent with small side effects, efficacy, and drug delivery is convenient.In a large number of clinical trials and continuous clinical application, it showed the good effect for the treatment of advanced breast cancer, which was expected to become the first-line chemotherapy drug for breast cancer treatment in the future. |
| keywords:S-1 advanced breast cancer chemotherapy drug |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
